First Patient Dosed in SOFIE Biosciences' Phase 3 Study for Pancreatic Cancer

SOFIE Biosciences Begins Pivotal Phase 3 Study for Pancreatic Cancer

SOFIE Biosciences, a well-established manufacturer in the field of radiopharmaceuticals based in the United States, has recently marked a significant milestone in cancer diagnostics. The company announced that the initial patient has been dosed in a critical Phase 3 trial known as the FAPI-PRO study, which aims to evaluate the efficacy of [18F]FAPI-74 in diagnosing Pancreatic Ductal Adenocarcinoma (PDAC).

This innovative diagnostic tool, labeled with fluorine-18, targets the Fibroblast Activation Protein (FAP) that is often overexpressed in various cancers, particularly in pancreatic tumors. The significance of this trial cannot be understated as pancreatic cancer is known for its poor prognosis and late-stage diagnosis. Thus, an effective diagnostic method could greatly improve patient outcomes.

Philipp Czernin, Chief Business Officer at SOFIE, expressed that this advancement is a noteworthy leap forward in assessing FAPI's role as a diagnostic instrument in oncology. The conviction in this trial stems from promising outcomes seen in earlier Phase 2 studies, along with independent research conducted by academic investigators. These prior studies have highlighted the potential of [18F]FAPI-74 to enhance the accuracy of staging in pancreatic cancer, which is critically needed in the clinical community.

Moreover, Dr. Gary Ulaner from the Hoag Family Cancer Institute emphasized the appeal of [18F]FAPI-74 PET for both patients and clinicians. The importance of precise staging in making informed decisions about the optimal treatment pathways cannot be overstated. The collaborative enthusiasm among healthcare professionals, including surgeons and oncologists, reflects the hope that this diagnostic tool brings.

The FAPI-PRO trial is set to be an extensive study involving multiple sites. It will adopt an open-label, non-randomized design with a single dose administration aimed at assessing the clinical utility of [¹⁸F]FAPI-74 PET/CT in detecting metastatic disease in adults diagnosed with PDAC. Projections estimate the inclusion of about 200 participants across 18 different sites, with the trial spearheading over the next two years. The study's primary objectives will focus on determining the sensitivity and specificity of the diagnostic tool in identifying distant metastasis (M1).

In parallel to the FAPI-PRO trial, there is another Phase 3 study known as FAPI-GO, which targets gastroesophageal cancers. This study commenced in November 2025, and its initial patient was dosed by the end of the year. This trial follows a similar methodology and is evaluating the utility of [¹⁸F]FAPI-74 PET/CT within this cancer category.

Understanding the underlying technology, [18F]FAPI-74 stands as the primary member of the FAPI compound family. Its favorable dosimetry, avidity, safety profile, and biodistribution make it particularly effective in identifying FAP-expressing cells that populate various tumors. As SOFIE continues the optimization process for its production, the future technical developments of this radioligand in clinical settings are highly anticipated.

FAP, or Fibroblast Activation Protein, is abundantly present in cancer-associated fibroblasts and contributes significantly to the tumor microenvironment. FAPI technologies, developed primarily by researchers at Heidelberg University Hospital, show promising initial clinical and preclinical findings, suggesting their role in improving diagnostic and therapeutic strategies against cancer, particularly when used in conjunction with existing treatments like chemotherapy, immunotherapies, or radiation.

SOFIE is committed to advancing healthcare through its innovative approach to molecular diagnostics and therapeutics (theranostics). With a comprehensive production and distribution network for radiopharmaceuticals, as well as contract manufacturing services, SOFIE remains at the forefront of developing effective cancer treatments. For more details on this groundbreaking study, interested parties are encouraged to visit ClinicalTrials.gov to access more information including trial identifiers for this and related studies.